EUCTR2014-002146-44-BE进行中（未招募）1 期
Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years) PROTOCOLE GRAALL-2014 - GRAALL-2014
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,040
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •General criteria :
- •1. Whose blood and bone marrow explorations have been completed before the steroids prephase
- •2. Aged 18 to 59 years old with not previously treated ALL (including intrathecal injections) newly diagnosed according to the WHO 2008 definition with > or = 20% bone marrow blasts
- •3. Without other evolving cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix) or its treatment should be finished at least since 6 months
- •4. With ECOG < or = 3
- •5. With or without central nervous system (CNS) or testis involvement
- •6. Who have received or being receiving the steroid prephase
- •7. With efficient contraception for women of childbearing age (excluding estrogens and IUS)
- •8. Having signed a written informed consent
- •9. With health insurance coverage
- •GRAALL-2014/B specific:
- •1. With B-ALL
- •2. Whose karyotype shows no t(9;22) and/or the absence in molecular biology of BCR-ABL marker
- •GRAALL-2014/T specific:
- •1. With T-ALL
- •ATRIALL specific:
- •1. Included in GRAALL-2014/T
- •2. With HR T-ALL
- •3. ECOG < or = 2
- •4. In CR after one or two induction cures and having received the three blocks of consolidation 1
- •5. Without documented CNS involvement at diagnosis
- •6. With or without allogeneic donor
- •GRAAPH-2014 specific:
- •1. With Ph+ ALL (confirmed diagnosis of the Philadelphia chromosome defined by the reciprocal translocation of chromosomes 9 and 22, t(9;22) and/or presence of the BCR-ABL molecular maker)
- •2. Having received no previous treatment for this hemopathy (including IT injection)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1040
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Principal criteria:
- •1. Myocardial infarction within 6 months prior to inclusion in the trial, cardiomyopathy, LEVF <50% and or RF <30%
- •2. Women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least three months thereafter. Patients not willing to ensure not to beget a child during participation in the study and at least three months thereafter
- •3. Not able to bear with the procedures or the frequency of visits planned in the trial
- •4. Unable to consent, under tutelage or curatorship, or judiciary safeguard
- •5. Treated with any other investigational agent or participation in another trial within 30 days prior to entering this study
- •GRAALL-2014/B:
- •1. With lymphoblastic lymphoma and bone marrow blasts <20%, Burkitt-type ALL or with antecedents of CML or other myeloproliferative neoplasm
- •2. HIV, HTLV-I or HCV seropositivity or chronic HBV hepatitis (HbsAg-positive)
- •3. With contra-indication of anthracyclines or any other general or visceral contra-indication to intensive therapy except if considered related to the ALL:
- •a.AST or ALT >5 x ULN
- •b.Total bilirubin >or= 2.5 x ULN
- •c.Creatinine >1.5 x ULN or creatinine clearance <50 mL/mn
- •GRAAL-2014/T:
- •1. With lymphoblastic lymphoma and bone marrow blasts <20%, Burkitt-type ALL or with antecedents of CML or other myeloproliferative neoplasm
- •2. Other active malignancy
- •3. Women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least three months thereafter. Patients not willing to ensure not to beget a child during participation in the study and at least three months thereafter
- •4. Treated with any other investigational agent or participation in another trial within 30 days prior to entering this study
- •5. with severe evolving infection, or known HIV or HTLV1 seropositivity, or chronic hepatitis B (HbsAg-positive) or C
- •6. With contra-indication of anthracyclines or any other general or visceral contra-indication to intensive therapy except if considered related to the ALL:
- •a.AST or ALT >5 x ULN
- •b.Total bilirubin >or= 2.5 x ULN
- •c.Creatinine >1.5 x ULN or creatinine clearance <50 mL/mn
- •ATRIALL specific:
- •1. With ECOG status > or = 3 after consolidation 1
- •2. With CNS disease at diagnosis, or symptomatic CNS disease, or uncontrolled epilepsy
- •3. With peripheral neuropathy grade >or= 2 after consolidation 1
- •4. With abnormal laboratory values as defined below after consolidation 1
- •a. AST and/or ALT >or= 5 x ULN
- •b. Total bilirubin >or= 1.5 x ULN
- •c. Creatinine >or= 1.5 x ULN or creatinine clearance <50 ml/min
- •d. Serum amylase and lipase >or= 1.5 x ULN
- •5. With active uncontrolled infection, any other concurrent disease or medical conditionthat is deemed to interfere with the conduct of the study as judged by the investigator
- •6. With childbearing potential not willing to use an effective form of contraception during participation in the study and at least three months thereafter. Patients not willing to ensure not to beget a child during participation in the study and at least three months thereafter
- •7. With known hypersensitivity to nelarabine
- •GRAAPH-2014:
- •1. Previously treated with Tyrosine Kinase Inhibitor
- •2. With another active malignancy
- •3. With general or visceral contra-indication to intensive therapy (except if considered related to the ALL):
- •a. ASAT and/or ALAT>or= 2.5 x ULN
- •b. Total bilirubin >1.5 x ULN
研究者
相似试验
进行中（未招募）
1 期
Multicenter trial for the treatment of acute Hepatitis C with Sofosbuvir/VelpatasvirEUCTR2018-003474-27-DEHannover Medical School20
进行中（未招募）
不适用
A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathyneuropathic painMedDRA version: 6.0Level: LLTClassification code 10012680EUCTR2004-000960-28-DESCHWARZ BIOSCIENCES GmbH360
进行中（未招募）
1 期
A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathyPainful diabetic neuropathyMedDRA version: 6.0Level: LLTClassification code 10012680EUCTR2004-000960-28-ESSCHWARZ BIOSCIENCES GmbH360
进行中（未招募）
不适用
A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathyPainful diabetic neuropathyMedDRA version: 6.0Level: LLTClassification code 10012680EUCTR2004-000960-28-HUSCHWARZ BIOSCIENCES GmbH360
进行中（未招募）
不适用
A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathySubjects with neuropathic painMedDRA version: 9.1Level: HLGTClassification code 10034606Term: Peripheral neuropathiesEUCTR2004-000960-28-ITSCHWARZ PHARMA480